Linked Data API

Show Search Form

Search Results

156795
registered interest false more like this
date less than 2014-11-19more like thismore than 2014-11-19
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading Chemicals: Safety more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, if he will review the safety of the anti-bacterial agent Tricolsan; if he will place in the Library copies of reports his Department has received on the safety of this chemical in the last 12 months; and if he will make a statement. more like this
tabling member constituency West Bromwich East remove filter
tabling member printed
Mr Tom Watson more like this
uin 215165 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-11-24more like thismore than 2014-11-24
answer text <p>Triclosan is an antimicrobial agent that is present as an active ingredient in some pharmaceutical products, such as antiseptic skin solutions and medicinal toothpastes. As with all medicinal products, the Medicines and Healthcare products Regulatory Agency (MHRA) keeps the safety of triclosan-containing pharmaceuticals under continual review. The view of the MHRA is that the balance of risks and benefits of such products continues to be favourable. The MHRA is unaware of any new data relevant to humans to alter this view.</p><p> </p><p> </p><p> </p><p>Triclosan has also been used for more than 35 years in a wide range of consumer products for its antiseptic, disinfectant and preservative properties. This includes some soaps, cosmetics, detergents, shampoos, toothpastes and mouth washes.</p><p> </p> more like this
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-11-24T17:38:14.463Zmore like thismore than 2014-11-24T17:38:14.463Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1463
label Biography information for Lord Watson of Wyre Forest more like this
143398
registered interest false more like this
date less than 2014-11-07more like thismore than 2014-11-07
answering body
Department of Health more like this
answering dept id 17 more like this
answering dept short name Health more like this
answering dept sort name Health more like this
hansard heading NHS: Drugs more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health, if he will issue a direction under Regulation 7 of the National Institue for Health and Care Excellence (NICE) (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 to exempt clinical commissioning groups from the requirement to comply with NICE Technology Assessment Guidance TA155, in order that NHS commissioners can make their own decision on whether to issue the drug Avastin and Lucentis. more like this
tabling member constituency West Bromwich East remove filter
tabling member printed
Mr Tom Watson more like this
uin 213834 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2014-11-17more like thismore than 2014-11-17
answer text <p>We have no such plans. The Government believes that drugs and treatments that are established as clinically and cost effective should be available to patients. The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance on Lucentis (ranibizumab) and Macugen (pegaptanib) for the treatment of age-related macular degeneration (TA155) that recommends Lucentis as a clinically and cost effective use of National Health Service resources for the treatment of patients with wet age-related macular degeneration meeting specific clinical criteria.</p><p> </p><p> </p><p> </p><p>Under Regulation 7, commissioners are legally required to make funding available so that clinicians can prescribe treatments recommended in NICE technology appraisal guidance to patients. This does not prevent commissioners from supporting the use of additional treatment options if they believe they would be of benefit to their local population.</p><p> </p><p> </p><p> </p><p>Avastin (bevacizumab) is not licensed for use in the treatment of wet age-related macular degeneration. Clinicians are able to prescribe drugs outside their marketing authorisation where they believe it is clinical appropriate, based on an assessment of their patient’s individual clinical circumstances.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
answering member constituency Mid Norfolk more like this
answering member printed George Freeman remove filter
question first answered
less than 2014-11-17T11:14:36Zmore like thismore than 2014-11-17T11:14:36Z
answering member
4020
label Biography information for George Freeman more like this
tabling member
1463
label Biography information for Lord Watson of Wyre Forest more like this